Results 21 to 30 of about 2,055 (161)

Herzlichen Glückwunsch medinfo!! [PDF]

netbib, 2009
Edlef Stabenau
openaire   +3 more sources

Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r/r lymphoma. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 5, Page 1850-1853, May 2026.
Miles B, Mao D, Vardhanabhuti S, Bedognetti D, Filosto S, Shen R.   +5 more
europepmc   +2 more sources

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 2, Page 737-741, February 2026.
Komrokji RS, Santini V, Platzbecker U, Van Eygen K, Díez-Campelo M, de Paz R, Santillana GS, Thépot S, Kaźmierczak M, Oliva EN, Sekeres MA, Fenaux P, Madanat YF, Savona MR, Riggs J, Shah S, Lennox AL, Xia Q, Sun L, Berry T, Zeidan AM.   +20 more
europepmc   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]

Liver Int
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC, Gordon F, Thuluvath PJ, Victor D, Kemmer N, Cardoza S, Jamil K, Frederick RT.   +7 more
europepmc   +2 more sources

Maralixibat Reduces Serum Bile Acids and Improves Cholestatic Pruritus in Adolescents With Alagille Syndrome. [PDF]

Liver Int
ABSTRACT Background Alagille syndrome (ALGS) is a multisystem cholestatic disorder. Maralixibat is approved for the treatment of cholestatic pruritus in ALGS with limited data in adults. Methods Participants were included if they received ≥ 2 doses of maralixibat at age ≥ 16 years in one of the three previously published maralixibat ALGS clinical ...
Hirschfield G, Vandriel SM, Mogul DB, Baek M, Vig P, Kamath BM.   +5 more
europepmc   +2 more sources

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours. [PDF]

Clin Transl Med
Evidence suggests NOTCH activation is among the survival and proliferation pathways interacting with FOXL2 c.402C > G (p.Cys134Trp) mutation in granulosa cell tumours (GCT). This Phase II clinical trial of nirogacestat in GCT achieved its enrolment target in < 1 year and primary analysis within 2 years.
Grisham RN, Hopp E, Pennington K, Holloway R, Wenham RM, Blecharz P, Dockery L, Matsuo K, Salani R, Bidzinski M, Braly P, Celano P, Reid T, Seward S, Lewis J, Johnson M, DuBose R, Ahn S, Cheng S, Alvero C, Konstantinopoulos PA.   +20 more
europepmc   +2 more sources

MEDINFO‐maailmankongressi Kapkaupungissa

Finnish Journal of eHealth and eWelfare, 2009
Toimitus
doaj   +1 more source

A model of academic-practice collaboration for facilitating informatics capacity and building a learning health system framework in public health. [PDF]

Learn Health Syst
Abstract Background and Objective The data modernization initiative (DMI) is a multi‐year, multi‐billion‐dollar endeavor toward a robust public health information infrastructure. The various DMI projects (interoperability, analytics, workforce, governance) present an opportunity for a learning health system (LHS) framework in public health.
Rajamani S, Solarz S, Muscoplat MH, Schmit AD, Gonderinger A, Brueske C, Fritz J, Emerson E, Melton GB.   +8 more
europepmc   +2 more sources

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]

Aliment Pharmacol Ther
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS, Kwo P, Pappas SC, O'Leary JG, Jamil K, Cardoza S, Wong F.   +6 more
europepmc   +2 more sources

Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR)

Annals of Neurology, Volume 94, Issue 5, Page 955-968, November 2023., 2023
Objective Delandistrogene moxeparvovec is approved in the USA for the treatment of ambulatory patients (4–5 years) with Duchenne muscular dystrophy. ENDEAVOR (SRP‐9001‐103; NCT04626674) is a single‐arm, open‐label study to evaluate delandistrogene moxeparvovec micro‐dystrophin expression, safety, and functional outcomes following administration of ...
Craig M. Zaidman, Crystal M. Proud, Craig M. McDonald, Kelly J. Lehman, Natalie L. Goedeker, Stefanie Mason, Alexander P. Murphy, Maitea Guridi, Shufang Wang, Carol Reid, Eddie Darton, Christoph Wandel, Sarah Lewis, Jyoti Malhotra, Danielle A. Griffin, Rachael A. Potter, Louise R. Rodino‐Klapac, Jerry R. Mendell   +17 more
wiley   +1 more source